In another clinical analysis, Alshalalfa et al. (2022) found that compared to other sites of PC metastasis, PCLM was significantly associated with PTEN deletion (42% vs. 20%), as well as phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta (PIK3CB) amplification (8.2% vs. 0.9%) and myelocytomatosis oncogene (MYC) amplification (29.5% vs. 9.8%) [17]. The gene discussed is MYC; the disease is pachyonychia congenita.